50% Hemolysis Rate Assay Kit Testing: CH50 Complement Activity Analysis

The 50% hemolysis rate assay kit testing service provides accurate quantification of total complement activity (CH50) and hemolytic performance in serum, plasma, and biomedical samples. Using validated 50% hemolysis assay kits and spectrophotometric detection, accredited third-party laboratories deliver reliable results supporting clinical diagnostics, biopharmaceutical development, and medical device hemocompatibility evaluation in compliance with ISO 10993-4 and related standards.

Technical Overview

The 50% hemolysis rate assay, widely known as the CH50 (complement hemolysis 50) test, is a functional bioassay that quantifies the total lytic activity of the complement system. The assay determines the dilution or concentration of a test sample that lyses exactly 50% of a standardized suspension of antibody-sensitized erythrocytes, typically sheep red blood cells (SRBCs). Complement activation through the classical pathway generates the membrane attack complex (MAC, C5b-9), which perforates the erythrocyte membrane and releases hemoglobin into the surrounding medium.

Commercial 50% hemolysis rate assay kits standardize the critical reactants—sensitized erythrocytes, complement-fixing antibody, buffered diluent, and reference control serum—so that the endpoint can be measured reproducibly. Released hemoglobin is quantified spectrophotometrically at approximately 540–541 nm, and the resulting hemolysis curve is linearized using the Von Krogh logit transformation. This converts the sigmoidal dose–response relationship into a linear plot from which the precise 50% hemolytic endpoint (CH50 value, expressed in U/mL) is calculated.

A closely related variant, the AH50 assay, evaluates the alternative complement pathway using unsensitized rabbit erythrocytes in a magnesium-containing, calcium-chelated buffer system (EGTA–Mg²⁺). When CH50 and AH50 are performed together, the testing laboratory can distinguish whether a complement abnormality originates from the classical, lectin, or alternative pathway, which is essential for mechanistic interpretation of results.

Testing Samples

Human Clinical Specimens

Serum is the preferred matrix for 50% hemolysis rate testing. Blood is collected into plain tubes, allowed to clot at room temperature for 30–60 minutes, and centrifuged to obtain clear serum. Plasma anticoagulated with EDTA or heparin may be accepted where method validation demonstrates equivalence, although citrate and serum-separator tubes are generally avoided due to complement activation or adsorption artifacts.

Animal Serum from Preclinical Studies

Serum from mouse, rat, rabbit, guinea pig, and non-human primate species is routinely tested during immunotoxicology and pharmacology programs. Species-matched or species-compatible assay configurations are selected because complement reactivity differs across animals, and guinea pig serum, for example, exhibits particularly high classical pathway activity.

Biopharmaceutical and Biological Process Samples

Cell culture supernatants, monoclonal antibody formulations, fusion protein preparations, and process intermediates can be evaluated for complement-activating potential or residual hemolytic activity as part of immunogenicity and product safety characterization.

Medical Device Extracts and Blood-Contacting Materials

Extraction fluids from catheters, stents, oxygenators, dialysis membranes, coatings, and other blood-contacting devices are tested to determine the hemolysis rate of material leachables, supporting hemocompatibility assessment under ISO 10993-4, ASTM F756, and GB/T 16886.4 frameworks.

Testing Items

Accredited third-party laboratories offering 50% hemolysis rate kit testing typically cover the following analytical parameters:

• Total complement activity via the classical pathway (CH50, reported in U/mL)
• Alternative pathway activity (AH50, reported in U/mL)
• Calculated hemolysis rate (%) for device extracts and material contact tests
• Hemolytic endpoint titer and reciprocal dilution at 50% lysis
• Semi-quantitative complement activity grading against reference serum standards
• Specimen integrity screening, including hemolysis index, lipemia, and icterus interference checks
• Complementary C3 and C4 quantification to localize pathway deficiencies when CH50 is depressed

Testing Methods

The reference functional method is based on the classical Mayer-style hemolytic assay adapted to a kit format. A serial dilution series of the test serum is incubated with a fixed volume of antibody-sensitized SRBC suspension at 37 °C for a controlled incubation period, typically 30–60 minutes. The reaction is stopped, unlysed cells are pelleted by centrifugation, and hemoglobin release in the supernatant is measured by UV-visible spectrophotometry at 540–541 nm.

Data processing follows a defined quality-controlled workflow:

• Construction of the hemolysis curve with 0% lysis (buffer blank) and 100% lysis (water or ammonium chloride lysis) controls
• Normalization of absorbance values to percentage hemolysis
• Linearization using the Von Krogh equation, plotting log(sample volume) versus log(y/(1−y))
• Interpolation of the 50% endpoint and conversion into CH50 units per milliliter
• Verification against an internal reference serum and lot-specific calibration criteria

Method performance is governed by documented validation parameters, including precision (intra-assay and inter-assay coefficient of variation), accuracy against reference material, linearity, limit of quantification, and matrix-specific interference assessment. Specimen handling is critical because complement proteins are thermolabile: serum should be separated promptly, aliquoted, frozen at −70 °C or below, and shipped on dry ice with avoidance of repeated freeze–thaw cycles. For device-related testing, the direct contact and extract-based incubation protocols of ISO 10993-4 and GB/T 16886.4 are applied, with hemolysis rates conventionally considered acceptable at or below the 5% threshold referenced in ASTM F756 and GB/T 16886.4.

Applications

50% hemolysis rate assay kit testing supports decision-making across clinical, regulatory, and research domains:

• Clinical immunology: screening for complement component deficiencies and monitoring disease activity in systemic lupus erythematosus, immune complex disorders, and glomerulonephritis
• Therapeutic drug monitoring: assessing complement inhibition during monoclonal antibody therapy targeting C5 and related pathways
• Biopharmaceutical safety evaluation: characterizing complement-activating properties of antibodies, nanoparticle carriers, and lipid-based formulations in accordance with immunotoxicity testing expectations such as ICH S6(R1) and ICH S8
• Medical device hemocompatibility: demonstrating compliance of blood-contacting devices with ISO 10993-4, ASTM F756, and GB/T 16886.4 requirements for regulatory submissions
• Infection and inflammation research: investigating complement consumption in sepsis, post-infectious immune dysregulation, and transplant-related inflammation
• Vaccine and adjuvant development: evaluating innate immune activation profiles of candidate formulations
• Cosmetics, surfactants, and botanical extracts: determining hemolytic potential as part of safety screening before dermal or mucosal exposure assessments

FAQ

What is the difference between CH50 and AH50 testing?

CH50 measures the total functional activity of the classical complement pathway using antibody-sensitized sheep erythrocytes, whereas AH50 measures the alternative pathway using rabbit erythrocytes in EGTA–Mg²⁺ buffer. Running both assays in parallel helps localize the defective pathway when results are abnormal.

Which sample type is acceptable, and how should it be shipped?

Serum is the recommended matrix. Samples should be centrifuged after clotting, aliquoted to avoid freeze–thaw cycles, frozen at −70 °C or below, and shipped on dry ice. Complement activity declines rapidly at ambient temperature, so cold-chain integrity is essential for valid results.

Can a CH50 result identify which complement protein is deficient?

No. CH50 is a global functional screening assay. A depressed CH50 indicates reduced total pathway activity but does not identify the individual component involved; follow-up testing such as C3, C4, MBL, or factor B measurement, and targeted functional or genetic assays, is recommended for confirmation.

What is the acceptance criterion for medical device hemolysis testing?

Under ISO 10993-4, ASTM F756, and GB/T 16886.4 conventions, a hemolysis rate of 5% or below is generally regarded as acceptable for blood-contacting materials, with values above that threshold triggering material redesign or extractable-leachable investigation.

What is the typical turnaround time?

Most accredited third-party laboratories report 50% hemolysis rate kit test results within 5 to 10 business days after sample receipt, depending on assay scope, validation requirements, and the complexity of the test matrix.